RecruitingPhase 1NCT05083754

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal Investigator
Lawrence Kleinberg, MD
Johns Hopkins University
Intervention
Retifanlimab(drug)
Enrollment
50 enrolled
Eligibility
18-100 years · All sexes
Timeline
20222029

Study locations (1)

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05083754 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials